CARsgen reported FY 2025 revenue of CNY 125.7 million, mainly from zevor-cel, and FY 2025 gross profit of about CNY 80 million. The company posted a FY 2025 net loss of about CNY 103 million, down about 87% YoY. Cash and cash equivalents were about CNY 1.1 billion as of Dec. 31, 2025, and CARsgen said cash and cash equivalents at the end of 2026 are expected to be not less than CNY 1.0 billion. For 2025 commercialization, CARsgen said it received 218 confirmed zevor-cel orders from partner Huadong Medicine, and noted zevor-cel was included in China’s Commercial Health Insurance Innovative Drug Catalogue (2025) in December 2025. On the pipeline, the company said China’s regulator accepted the NDA for satri-cel and granted Priority Review; CARsgen expects satri-cel to be approved in H1 2026 and initiate commercialization. CARsgen also highlighted progress in allogeneic CAR-T development and its lentiviral-based in vivo CAR T-cell CARvivo platform, and disclosed a Feb. 12, 2026 strategic cooperation agreement to establish a CAR-T commercial manufacturing base in Jinshan District, Shanghai, with total investment not exceeding CNY 370 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603060703PR_NEWS_USPR_____CN03234) on March 06, 2026, and is solely responsible for the information contained therein.